Pulmonary function tests in the two groups measured at the on-site visits#
| Measure | Group | Week 2 | Week 4 | Week 8 | Week 12 | p-value |
| FEV1 L | BDP/F | 0.26±0.38 | 0.29±0.46 | 0.33±0.49 | 0.28±0.47 | 0.354 |
| BUD/F | 0.33±0.41 | 0.37±0.44 | 0.40±0.44 | 0.33±0.44 | ||
| FVC L | BDP/F | 0.23±0.47 | 0.27±0.53 | 0.33±0.54 | 0.26±0.52 | 0.557 |
| BUD/F | 0.26±0.49 | 0.31±0.53 | 0.34±0.52 | 0.21±0.52 | ||
| PEF L·min−1 | BDP/F | 52.29±72.81 | 59.99±74.03 | 63.66±74.28 | 56.04±72.97 | 0.806 |
| BUD/F | 55.71±74.35 | 57.47±71.25 | 64.36±75.94 | 53.16±77.29 | ||
| MEF50% L·s−1 | BDP/F | 0.42±0.66 | 0.43±0.71 | 0.48±0.84 | 0.43±0.82 | 0.512 |
| BUD/F | 0.48±0.69 | 0.53±0.75 | 0.63±0.86 | 0.50±0.80 |
Data are presented as mean±sd, unless otherwise stated. FEV1: forced expiratory volume in one second; FVC: forced vital capacity; PEF: peak expiratory flow; MEF50%: mid-expiratory flow at 50% vital capacity; BDP/F: beclomethasone/formoterol; BUD/F: budesonide/formoterol. The p-values refer to comparison between groups in final values (week 12, last visit). #: mean changes from baseline (intention-to-treat population)